Differences

This shows you the differences between two versions of the page.

--- pharmaceutical_companies:glaxosmithkline [2022/04/28 17:48]
liam [Research Funding]
+++ pharmaceutical_companies:glaxosmithkline [2022/10/06 18:25] (current)
pamela [[[:Google]] Partnership]
@@ Line 14: / Line 14: @@
 On November 10, 2011, GSK announced the launch of the $50 million GSK Canada Life Sciences Innovation Fund to advance the commercialization of scientific innovation in Canada by investing in early stage breakthrough research.((Robinson, A., & Minicucci, D. (2011, November 10). //GlaxoSmithKline Inc. Launches $50 Million Life Sciences Innovation Fund in Canada.// Wayback Machine; GlaxoSmithKline. https://web.archive.org/web/20160505194118/http://ca.gsk.com/media/525823/2011-11-10.pdf))
+==== Google Partnership ====
+{{ :pharmaceutical_companies:gsk_google_verily.png?400|}}
+Google Parent and GlaxoSmithKline Are Creating a $715 Million Bioelectronics Firm.
+GSK and [[:Google]] Alphabet's Verily create $715M joint venture in bioelectronics
+by Ben Adams | Augist 1, 2016
+GlaxoSmithKline ($GSK) has announced a major new joint venture with [[:Verily]] --once [[:Google Life Sciences]] --as the two join forces with the hope of creating the first generation of bioelectronic medicines for chronic diseases.
+GSK has been working on this bioelectronic approach since 2012--an approach that aims to disrupt certain electronic signals in the body through tiny implanted devices in the hope of altering the pathways of a number of diseases and conditions.
+It’s stumped up around $50 million in VC cash in that time, but today is taking a much larger leap into this burgeoning area where tech meets biology by putting down £540 million ($715 million) over the next 7 years into a JV with Verily, which will focus on building devices that target arthritis, diabetes and asthma.
+Verily, a part of [[:Alphabet]] ($GOOG) and graduating from its secretive [[:Google X division]], has recently become its own unit, with a focus on big data and devices, such as a "smart" contact lens and surgical robots.
+The company has already attracted the attention of a number of Big Pharmas, having tie-ups with [[:Sanofi]] ($SNY) in diabetes and already signing a JV with [[:Johnson & Johnson]] ($JNJ) to create a company known as Verb Surgical, which aims to make new kinds of robotic surgical systems. It also has a deal with [[:Dexcom]] ($DXCM) that has seen the two publicly declare their ambition to launch a mini glucose monitor by 2018.
+Its latest iteration, called [[:Galvani Bioelectronics]] (after the Italian 18th century pioneer in the field of bioelectricity Luigi Aloisio Galvani), will be 55% owned by GSK and 45% by Verily. The R&D arms will be split between GSK’s research base in Stevenage, U.K., and Verily’s facilities in South San Francisco--but its official headquarters will be in the U.K. ((https://web.archive.org/web/20160802185529/https://www.fiercebiotech.com/medical-devices/gsk-and-google-s-verily-create-715m-joint-venture-bioelectronics))
 ==== COVID-19 ====